Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Monday, November 20th, RTT News reports. Investors of record on Friday, December 8th will be given a dividend of 0.75 per share by the medical instruments supplier on Friday, December 29th. This represents a $3.00 annualized dividend and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, December 7th. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73.
Becton, Dickinson and has increased its dividend by an average of 10.1% per year over the last three years and has raised its dividend every year for the last 45 years. Becton, Dickinson and has a dividend payout ratio of 28.2% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Becton, Dickinson and to earn $11.80 per share next year, which means the company should continue to be able to cover its $3.00 annual dividend with an expected future payout ratio of 25.4%.
Shares of Becton, Dickinson and (BDX) opened at $219.07 on Wednesday. The company has a market capitalization of $49,909.01, a PE ratio of 23.07, a P/E/G ratio of 1.71 and a beta of 1.07. Becton, Dickinson and has a 1-year low of $161.29 and a 1-year high of $229.68. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44.
Several analysts have commented on BDX shares. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Royal Bank Of Canada reissued a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, October 9th. Morgan Stanley raised their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $245.00 price objective on shares of Becton, Dickinson and in a report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $217.08.
In related news, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.